Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis

Area of Science:

• Critical Care Medicine
• Pulmonology
• Pharmacology

Background:

• Acute respiratory distress syndrome (ARDS) is a severe condition with high mortality.
• Aviptadil, a vasoactive intestinal peptide (VIP) analogue, has anti-inflammatory and cytoprotective properties.
• The efficacy of aviptadil in improving ARDS patient survival is not well-established.

Purpose of the Study:

• To systematically review and meta-analyze the effectiveness of aviptadil in ARDS.
• To evaluate aviptadil's impact on survival and oxygenation in ARDS patients.

Main Methods:

• A comprehensive literature search was performed across six major databases.
• Included studies were screened by two independent investigators.
• Meta-analysis used a random-effects model; risk of bias was assessed using RoB 2 and JBI tools.

Main Results:

• Nine studies (2 RCTs, 7 case series) with 665 patients were analyzed.
• Meta-analysis of RCTs showed no significant survival benefit for aviptadil (OR: 1.01, p=0.93).
• Case series indicated improved oxygenation and reduced inflammation with aviptadil therapy.

Conclusions:

• Aviptadil may improve oxygenation and reduce inflammation in ARDS.
• Current evidence does not support a significant survival benefit of aviptadil in ARDS.
• Larger, well-designed RCTs are necessary to confirm aviptadil's therapeutic potential.